Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
XBRANE.ST Stock Summary
In the News
XBRANE.ST Financial details
Company Rating
Neutral
Market Cap
923.93M
Income
-388.15M
Revenue
238.68M
Book val./share
0.65
Cash/share
0.25
Dividend
-
Dividend %
-
Employees
93
Optionable
No
Shortable
Yes
Earnings
16 May 2024
P/E
-0.9
Forward P/E
0.05
PEG
-0.3
P/S
1.39
P/B
0.79
P/C
1.21
P/FCF
-0.57
Quick Ratio
0.43
Current Ratio
1.75
Debt / Equity
1.1
LT Debt / Equity
0.66
-
-
EPS (TTM)
-8.73
EPS next Y
5.72
EPS next Q
-
EPS this Y
-77.3%
EPS next Y
-165.56%
EPS next 5Y
-101.15%
EPS last 5Y
-36.63%
Revenue last 5Y
231.09%
Revenue Q/Q
13.59%
EPS Q/Q
-78.42%
-
-
-
-
SMA20
-
SMA50
-87.5%
SMA100
-95.45%
Inst Own
-
Inst Trans
-
ROA
-33%
ROE
-76%
ROC
-0.58%
Gross Margin
27%
Oper. Margin
-151%
Profit Margin
-151%
Payout
-
Shs Outstand
1.36B
Shs Float
1.29B
-
-
-
-
Target Price
-
52W Range
0.154405-104.2
52W High
-
52W Low
-
RSI
35
Rel Volume
8.26
Avg Volume
5.2M
Volume
42.91M
Perf Week
-72.84%
Perf Month
-87.33%
Perf Quarter
-98.52%
Perf Half Y
-98.93%
-
-
-
-
Beta
1.143
-
-
Volatility
0.14%, 0.64%
Prev Close
3.97%
Price
0.3015
Change
15.74%
XBRANE.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.05 | 0.38 | 0.49 | 2.25 | 0.94 | |
Net income per share | -14.97 | -12.52 | -8.1 | -6.74 | -1.53 | |
Operating cash flow per share | -13.28 | -13.16 | -9.31 | -7.58 | -1.61 | |
Free cash flow per share | -13.39 | -13.38 | -12.59 | -9.94 | -1.67 | |
Cash per share | 14.67 | 13.42 | 12.52 | 7.59 | 0.26 | |
Book value per share | 16.47 | 14.23 | 18.31 | 16.62 | 0.68 | |
Tangible book value per share | 10.59 | 10.78 | 16.2 | 12.63 | 0.68 | |
Share holders equity per share | 16.47 | 14.23 | 18.31 | 16.62 | 0.68 | |
Interest debt per share | 0.97 | 0.39 | 1.99 | 1.6 | 0.75 | |
Market cap | 387.17M | 1.35B | 2.47B | 2.1B | 2.53B | |
Enterprise value | 232.41M | 1.12B | 2.22B | 1.94B | 2.7B | |
P/E ratio | -2.31 | -5.97 | -12.94 | -12.19 | -6.52 | |
Price to sales ratio | 645.28 | 198.61 | 214.28 | 36.43 | 10.61 | |
POCF ratio | -2.61 | -5.68 | -11.25 | -10.83 | -6.23 | |
PFCF ratio | -2.58 | -5.59 | -8.32 | -8.26 | -5.98 | |
P/B Ratio | 2.1 | 5.26 | 5.72 | 4.94 | 14.78 | |
PTB ratio | 2.1 | 5.26 | 5.72 | 4.94 | 14.78 | |
EV to sales | 387.35 | 163.88 | 192.54 | 33.73 | 11.3 | |
Enterprise value over EBITDA | -1.48 | -5.11 | -13.25 | -11.71 | -9.75 | |
EV to operating cash flow | -1.56 | -4.69 | -10.11 | -10.02 | -6.63 | |
EV to free cash flow | -1.55 | -4.61 | -7.48 | -7.65 | -6.37 | |
Earnings yield | -0.43 | -0.17 | -0.08 | -0.08 | -0.15 | |
Free cash flow yield | -0.39 | -0.18 | -0.12 | -0.12 | -0.17 | |
Debt to equity | 0.05 | 0.02 | 0.1 | 0.09 | 1.1 | |
Debt to assets | 0.03 | 0.01 | 0.06 | 0.06 | 0.29 | |
Net debt to EBITDA | 0.98 | 1.08 | 1.5 | 0.94 | -0.6 | |
Current ratio | 1.78 | 1.98 | 2.55 | 2.17 | 1.41 | |
Interest coverage | -112.99 | -292.76 | -68.44 | -64.35 | -2.27K | |
Income quality | 0.89 | 1.05 | 1.17 | 1.12 | 1.26 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 44.03 | 4.57 | 2.72 | 0.55 | 0 | |
Research and developement to revenue | 192.86 | 29.81 | 13.93 | 3.47 | 1.28 | |
Intangibles to total assets | 0.19 | 0.13 | 0.07 | 0.15 | 0 | |
Capex to operating cash flow | 0.01 | 0.02 | 0.35 | 0.31 | 0.04 | |
Capex to revenue | -1.98 | -0.57 | -6.71 | -1.04 | -0.07 | |
Capex to depreciation | -0.16 | -0.59 | -5.95 | -3.63 | -0.5 | |
Stock based compensation to revenue | 3.49 | 0.19 | 0.39 | 0.15 | 0 | |
Graham number | 74.48 | 63.32 | 57.77 | 50.18 | 4.83 | |
ROIC | -0.82 | -0.83 | -0.36 | -0.34 | -0.93 | |
Return on tangible assets | -0.61 | -0.57 | -0.3 | -0.29 | -0.59 | |
Graham Net | 1.25 | 4.46 | 7.8 | -0.43 | -1.33 | |
Working capital | 108.32M | 185.49M | 341.34M | 276.96M | 135.14M | |
Tangible asset value | 118.51M | 195.17M | 382.07M | 322.89M | 171.34M | |
Net current asset value | 93.32M | 168.43M | 304.32M | 247.9M | -20.48M | |
Invested capital | 0.05 | 0.02 | 0.1 | 0.09 | 1.1 | |
Average receivables | 8.19M | 32.13M | 54.31M | 48.85M | 40.83M | |
Average payables | 26M | 25.32M | 35.47M | 32.35M | 27.14M | |
Average inventory | 2.76M | 0 | 107.79M | 132.92M | 78.56M | |
Days sales outstanding | 3.58K | 3.12K | 1.59K | 300.63 | 52.31 | |
Days payables outstanding | 421.46 | 2.47K | 1.24K | 512.99 | 55.6 | |
Days of inventory on hand | 0 | 0 | 6.44K | 1.11K | 191.81 | |
Receivables turnover | 0.1 | 0.12 | 0.23 | 1.21 | 6.98 | |
Payables turnover | 0.87 | 0.15 | 0.3 | 0.71 | 6.56 | |
Inventory turnover | 0 | 0 | 0.06 | 0.33 | 1.9 | |
ROE | -0.91 | -0.88 | -0.44 | -0.41 | -2.27 | |
Capex per share | -0.11 | -0.21 | -3.28 | -2.35 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.82 | 2.25 | 1.81 | 2.01 | 0.25 | |
Net income per share | -2.36 | -2.12 | -3.23 | -2.78 | -0.6 | |
Operating cash flow per share | -4.5 | -2.06 | -5.04 | -4.29 | -0.31 | |
Free cash flow per share | -4.87 | -2.64 | -5.1 | -4.3 | -0.31 | |
Cash per share | 7.59 | 4.32 | 11.19 | 5.72 | 0.25 | |
Book value per share | 16.62 | 13.36 | 14.18 | 11.33 | 0.65 | |
Tangible book value per share | 12.63 | 13.36 | 14.18 | 11.33 | 0.65 | |
Share holders equity per share | 16.62 | 13.36 | 14.18 | 11.33 | 0.65 | |
Interest debt per share | 1.52 | 1.49 | 8.76 | 8.26 | 0.74 | |
Market cap | 2.1B | 2.36B | 2.18B | 795.28M | 2.63B | |
Enterprise value | 1.94B | 2.28B | 2.11B | 869.4M | 2.8B | |
P/E ratio | -8.68 | -10.12 | -5.98 | -2.45 | -4.17 | |
Price to sales ratio | 100.63 | 38.23 | 42.63 | 13.5 | 39.31 | |
POCF ratio | -18.25 | -41.7 | -15.33 | -6.34 | -32.41 | |
PFCF ratio | -16.87 | -32.58 | -15.13 | -6.33 | -32.34 | |
P/B Ratio | 4.94 | 6.43 | 5.45 | 2.4 | 15.35 | |
PTB ratio | 4.94 | 6.43 | 5.45 | 2.4 | 15.35 | |
EV to sales | 93.16 | 36.96 | 41.25 | 14.76 | 41.79 | |
Enterprise value over EBITDA | -35.49 | -39.9 | -23.78 | -9.69 | -42.38 | |
EV to operating cash flow | -16.89 | -40.31 | -14.84 | -6.93 | -34.46 | |
EV to free cash flow | -15.62 | -31.5 | -14.64 | -6.92 | -34.38 | |
Earnings yield | -0.03 | -0.02 | -0.04 | -0.1 | -0.06 | |
Free cash flow yield | -0.06 | -0.03 | -0.07 | -0.16 | -0.03 | |
Debt to equity | 0.09 | 0.11 | 0.61 | 0.73 | 1.1 | |
Debt to assets | 0.06 | 0.06 | 0.25 | 0.27 | 0.29 | |
Net debt to EBITDA | 2.84 | 1.37 | 0.79 | -0.83 | -2.52 | |
Current ratio | 2.17 | 1.83 | 1.99 | 1.75 | 1.41 | |
Interest coverage | -95.39 | -93.43 | -45.84 | 0 | -13.62 | |
Income quality | 1.89 | 0.97 | 1.56 | 1.54 | 0.88 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.53 | 0.19 | 0.22 | 0.14 | 0 | |
Research and developement to revenue | 2.85 | 0.94 | 1.71 | 1.38 | 1.18 | |
Intangibles to total assets | 0.15 | 0.17 | 0.11 | 0.11 | 0 | |
Capex to operating cash flow | 0.08 | 0.28 | 0.01 | 0 | 0 | |
Capex to revenue | -0.45 | -0.26 | -0.04 | 0 | 0 | |
Capex to depreciation | -2.18 | -1.79 | -0.26 | -0.02 | -0.01 | |
Stock based compensation to revenue | 0.42 | 0 | 0 | 0 | 0 | |
Graham number | 29.73 | 25.25 | 32.07 | 26.61 | 2.96 | |
ROIC | -0.12 | -0.13 | -0.13 | -0.14 | -0.35 | |
Return on tangible assets | -0.1 | -0.11 | -0.1 | -0.1 | -0.24 | |
Graham Net | -0.43 | -4.53 | 2.42 | -9.53 | -1.28 | |
Working capital | 276.96M | 209.19M | 405.63M | 296.51M | 135.14M | |
Tangible asset value | 322.89M | 259.58M | 293.49M | 228.87M | 171.34M | |
Net current asset value | 247.9M | 178.86M | 217.1M | 130.48M | -20.48M | |
Invested capital | 0.09 | 0.11 | 0.61 | 0.73 | 1.1 | |
Average receivables | 25.87M | 32.55M | 211.31M | 233.61M | 48.22M | |
Average payables | 26.96M | 31.65M | 37.13M | 35.37M | 33.74M | |
Average inventory | 25.13M | 52M | 74.47M | 114.44M | 120.26M | |
Days sales outstanding | 204.73 | 25.71 | 713.26 | 95.11 | 46.03 | |
Days payables outstanding | 487.05 | 77.3 | 77.77 | 60.01 | 44.49 | |
Days of inventory on hand | 1.05K | 103.82 | 216.21 | 219.77 | 153.49 | |
Receivables turnover | 0.44 | 3.5 | 0.13 | 0.95 | 1.96 | |
Payables turnover | 0.18 | 1.16 | 1.16 | 1.5 | 2.02 | |
Inventory turnover | 0.09 | 0.87 | 0.42 | 0.41 | 0.59 | |
ROE | -0.14 | -0.16 | -0.23 | -0.25 | -0.92 | |
Capex per share | -0.37 | -0.58 | -0.07 | -0.01 | 0 |
XBRANE.ST Frequently Asked Questions
What is Xbrane Biopharma AB (publ) stock symbol ?
Xbrane Biopharma AB (publ) is a SE stock and trading under the symbol XBRANE.ST
What is Xbrane Biopharma AB (publ) stock quote today ?
Xbrane Biopharma AB (publ) stock price is $0.3015 today.
Is Xbrane Biopharma AB (publ) stock public?
Yes, Xbrane Biopharma AB (publ) is a publicly traded company.